telcagepant profile

telcagepant: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	11319053
CHEMBL ID	236593
SCHEMBL ID	1198535
MeSH ID	M0535916

Synonym
n-(6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl)-4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide
mk 0974
n-((3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)hexahydro-1h-azepin-3- yl)-4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide
mk0974
HY-32709
n-[(3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-3h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
gtpl703
telcagepant
mk-0974
bdbm50224431
CHEMBL236593 ,
telcagepant (usan)
781649-09-0
D09391
n7r ,
n-[(3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
telcagepant [usan:inn]
1-piperidinecarboxamide, n-((3r,6s)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1h-azepin-3-yl)-4-(2,3-dihydro-2-oxo-1h-imidazo(4,5-b)pyridin-1-yl)-
unii-d42o649all
d42o649all ,
n-((3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)hexahydro-1h-azepin-3-yl)-4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxamide
n-[(3r,6s)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1h-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxamide
CS-0291
AKOS015900692
1-piperidinecarboxamide, n-((3r,6s)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2- trifluoroethyl)-1h-azepin-3-yl)-4-(2,3-dihydro-2-oxo-1h-imidazo(4,5-b)pyridin-1-yl)-
telcagepant [usan]
telcagepant [who-dd]
telcagepant [inn]
telcagepant [mart.]
telcagepant [mi]
3N7R
n-[(3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyri din-1-yl)piperidine-1-carboxamide
SCHEMBL1198535
n-((3r,6s)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl)-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
NCGC00378827-01
n-[(3r,6s)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1h-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarbo
DB12228
BCP07257
Q5675567
mk 0974, telcagepant
F83529
MS-30255
DTXSID50999410
n-[(3r,6s)-6-(2,3-difluorophenyl)hexahydro-2-oxo-1-(2,2,2-trifluoroethyl)-1h-azepin-3-yl]-4-(2,3-dihydro-2-oxo-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxamide;telcagepant
A903524

Excerpt	Reference
"Telcagepant (MK-0974) is a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist and is currently under clinical development. "	( A flexible and high throughput liquid chromatography-tandem mass spectrometric assay for the quantitation of telcagepant in human plasma. Du, L; Martucci, AN; Miller-Stein, CM; Valesky, RJ; Woolf, EJ, 2009)
"Telcagepant is an oral calcitonin-gene related peptide (CGRP) receptor antagonist that is being developed by Merck & Co Inc for the treatment of migraine. "	( Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Cleves, C; Tepper, SJ, 2009)
"Telcagepant is a novel, orally active, and selective calcitonin gene-related peptide receptor antagonist being developed for acute treatment of migraine with and without aura. "	( Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. Blanchard, RL; Boyle, J; Ermlich, S; Gutierrez, M; Han, TH; Hickey, L; Laethem, T; Lines, C; McCrea, JB; Murphy, MG; Palcza, J; Panebianco, D; Sinclair, S; Van Bortel, L; Willson, K; Xiao, AJ; Xu, Y, 2010)
"Telcagepant is an oral calcitonin gene-related peptide receptor antagonist with acute antimigraine efficacy comparable to oral triptans. "	( Antimigraine efficacy of telcagepant based on patient's historical triptan response. Dodick, DW; Ferrari, MD; Ho, TW; Kost, J; Lines, C; Olesen, J, 2011)
"Telcagepant is an oral calcitonin gene-related peptide receptor antagonist which is being evaluated for the acute treatment of migraine. "	( Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Brandes, J; Ceesay, P; Gottwald, R; Hewitt, DJ; Ho, TW; Lines, C; Lipton, RB; Martin, V; Schaefer, E, 2011)
"Telcagepant is a calcitonin gene-related peptide (CGRP) receptor antagonist being evaluated for acute migraine treatment. "	( A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina. Behm, MO; Bittar, N; Blanchard, RL; Chaitman, BR; Chodakewitz, JA; Chrysant, SG; Free, AL; Heirman, I; Ho, AP; Ho, TW; Kobalava, Z; Laethem, T; Martsevich, SY; Murphy, MG; Palcza, JS; Panebianco, DL; Rowe, JF, 2012)
"Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). "	( ACS chemical neuroscience molecule spotlight on Telcagepant (MK-0974). Hopkins, CR, 2011)

Excerpt	Reference
"Telcagepant has an excellent tolerability and can be used in migraine patients with cardiovascular co-morbidity."	( Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment. Tfelt-Hansen, P, 2011)

Excerpt	Reference
"Telcagepant does not cause vasoconstriction, one of the major limitations in the use of triptans, which are considered to be the standard of care for migraine."	( Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Cleves, C; Tepper, SJ, 2009)
"Telcagepant does not cause vasoconstriction, a major limitation in the use of triptans."	( New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Edvinsson, L; Linde, M, 2010)

Excerpt	Reference
"Pretreatment with telcagepant (10 nM to 1 microM) antagonized alphaCGRP-induced relaxation competitively in distal coronary arteries (pA(2) = 8.43 +/- 0.24) and proximal coronary arteries and coronary arterioles (1 microM telcagepant, giving pK(B) = 7.89 +/- 0.13 and 7.78 +/- 0.16, respectively)."	( Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. Chan, KY; Danser, AH; de Vries, R; Edvinsson, L; Eftekhari, S; Garrelds, IM; Hargreaves, RJ; Kane, SA; Kimblad, PO; Lynch, J; Maassenvandenbrink, A; van den Bogaerdt, AJ, 2010)

Excerpt	Reference
" Sustained pain-free response with no adverse events has been recommended as a composite endpoint which measures the efficacy and tolerability attributes that patients desire."	( Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Assaid, C; Dodick, DW; Ho, TW; Kost, J; Lines, C, 2011)
" Endpoints were 2-24-hour sustained pain freedom and no adverse events from 0-24 hours (SPF24NAE), 2-24 hour sustained pain relief and no adverse events from 0-24 hours (SPR24NAE), pain freedom at 2 hours and no adverse events from 0-24 hours (PF2NAE), and pain relief at 2 hours and no adverse events from 0-24 hours (PR2NAE)."	( Sustained pain freedom and no adverse events as an endpoint in clinical trials of acute migraine treatments: application to patient-level data from a trial of the CGRP receptor antagonist, telcagepant, and zolmitriptan. Assaid, C; Dodick, DW; Ho, TW; Kost, J; Lines, C, 2011)

Excerpt	Reference
" The terminal half-life was approximately 6 hours."	( Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. Blanchard, RL; Boyle, J; Ermlich, S; Gutierrez, M; Han, TH; Hickey, L; Laethem, T; Lines, C; McCrea, JB; Murphy, MG; Palcza, J; Panebianco, D; Sinclair, S; Van Bortel, L; Willson, K; Xiao, AJ; Xu, Y, 2010)

Excerpt	Reference
" Here we report on the pharmacological characterization of the first orally bioavailable CGRP receptor antagonist in clinical development, MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide]."	( Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related pept Burgey, CS; Corcoran, HA; Fay, JF; Graham, SL; Hershey, JC; Johnston, VK; Kane, SA; Koblan, KS; Moore, EL; Mosser, SD; Paone, DV; Salvatore, CA; Shaw, AW; Vacca, JP; Williams, TM, 2008)
" Here, we have summarized the progress made in recent years, including the identification and optimization of an orally bioavailable small molecule CGRP receptor antagonist."	( The tortuous road to an ideal CGRP function blocker for the treatment of migraine. Davis, CD; Xu, C, 2008)
" We aimed to assess the clinical profile of MK-0974 (telcagepant), an orally bioavailable antagonist of CGRP receptor."	( Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Assaid, C; Dodick, DW; Fan, X; Ferrari, MD; Froman, S; Galet, V; Ho, TW; Koppen, H; Kost, J; Leibensperger, H; Lines, C; Winner, PK, 2008)
"The underlying mechanism for low oral bioavailability of MK-0974, a potent calcitonin-gene related peptide (CGRP)-receptor antagonist, in monkeys and for species-dependent non-linear pharmacokinetics in monkeys and rats were investigated."	( Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Cui, D; Laspina, C; Miller-Stein, C; Prueksaritanont, T; Roller, S; Rowe, J; Wong, B, 2009)
" Attenuation of polar surface area and incorporation of a weakly basic indoline nitrogen led to compound 5, a potent antagonist with good oral bioavailability in three species."	( The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists. Bednar, RA; Bell, IM; Blair Zartman, C; Corcoran, HA; Fay, JF; Gallicchio, SN; Graham, SL; Hershey, JC; Johnston, VK; Kane, SA; Miller-Stein, CM; Moore, EL; Mosser, SD; Roller, SA; Salvatore, CA; Theberge, CR; Vacca, JP; Williams, TM; Wong, BK, 2009)
" In this large phase 3 clinical trial, we sought to confirm the efficacy of telcagepant, the first orally bioavailable CGRP receptor antagonist."	( Randomized, controlled trial of telcagepant for the acute treatment of migraine. Assaid, C; Connor, KM; Diener, HC; Fan, X; Fei, K; Ho, TW; Kost, J; Lines, C; Lucas, S; Shapiro, RE, 2009)
" For the orally bioavailable CGRP antagonist telcagepant 300 mg, the headache relief was only 55% in one phase III study."	( Is there an inherent limit to the efficacy of calcitonin gene-related peptide receptor antagonists in the acute treatment of migraine? A comment. Tfelt-Hansen, PC, 2009)
"To evaluate inhibition of capsaicin-induced increase in dermal blood flow (DBF) following telcagepant (MK-0974), a potent and selective orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist being developed for the acute treatment of migraine."	( Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Boyle, J; de Hoon, JN; de Lepeleire, I; Denney, WS; Depré, M; Hickey, L; Ho, TW; Kane, SA; Li, CC; Murphy, MG; Palcza, J; Sinclair, SR; Van der Schueren, BJ; Van Hecken, A; Vanmolkot, FH; Willson, KJ; Xiao, A; Xu, Y, 2010)
" BMS-742413 has good intranasal bioavailability in the rabbit and shows a robust, dose-dependent inhibition of CGRP-induced increases in marmoset facial blood flow."	( Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migr Cantor, GH; Chaturvedula, PV; Conway, CM; Davis, C; Denton, R; Dubowchik, GM; Keavy, D; Macci, R; Macor, JE; Mathias, N; Mercer, SE; Moench, P; Pin, SS; Schartman, R; Signor, L; Thalody, G; Whiterock, V; Xu, C, 2013)
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)

Excerpt	Reference
" However, recent data reported elevated transaminase levels when telcagepant was dosed daily rather than acutely."	( Telcagepant, a calcitonin gene-related peptide antagonist for the treatment of migraine. Cleves, C; Tepper, SJ, 2009)
" However, recent data reported elevated liver transaminases when telcagepant was dosed twice daily for three months for the prevention of migraine rather than acutely."	( The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Olesen, J; Villalón, CM, 2009)
"Geometric mean plasma concentrations after dosing with 300 mg and 800 mg telcagepant were 720 and 1146 nm, respectively, at 1 h, vs."	( Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Boyle, J; de Hoon, JN; de Lepeleire, I; Denney, WS; Depré, M; Hickey, L; Ho, TW; Kane, SA; Li, CC; Murphy, MG; Palcza, J; Sinclair, SR; Van der Schueren, BJ; Van Hecken, A; Vanmolkot, FH; Willson, KJ; Xiao, A; Xu, Y, 2010)
" Monkey PET studies with [(11)C]MK-4232 after intravenous dosing with CGRP-R antagonists validated the ability of [(11)C]MK-4232 to detect changes in CGRP-R occupancy in proportion to drug plasma concentration."	( In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. Bell, IM; Blanchard, R; Bormans, G; Cook, JJ; de Groot, T; de Hoon, J; De Lepeleire, I; Declercq, R; Derdelinckx, I; Evelhoch, JL; Fan, H; Gallicchio, SN; Gantert, L; Hargreaves, RJ; Hostetler, ED; Joshi, AD; Kane, SA; Kennedy, WP; Li, CC; Marcantonio, EE; Miller, P; O'Malley, S; Purcell, M; Reynders, T; Riffel, K; Salvatore, CA; Sanabria-Bohórquez, S; Selnick, HG; Sur, C; Van Hecken, A; Van Laere, K; Williams, M; Zeng, Z, 2013)

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
G	Vesicular stomatitis virus	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	23.9185	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	11.9877	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Receptor activity-modifying protein 1	Homo sapiens (human)	Ki	0.0008	0.0000	0.0003	0.0008	AID1657084
Calcitonin gene-related peptide 1	Rattus norvegicus (Norway rat)	Ki	1.2000	1.2000	1.2000	1.2000	AID625594
Calcitonin gene-related peptide 1	Homo sapiens (human)	IC50 (µMol)	0.0022	0.0001	0.0012	0.0022	AID625501
Calcitonin gene-related peptide 1	Homo sapiens (human)	Ki	50.0004	0.0000	2.4336	7.3000	AID625500; AID625501
Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)	IC50 (µMol)	0.0066	0.0000	0.0051	0.0110	AID1180676; AID1180677; AID302760; AID302761; AID431191; AID431192; AID444308; AID444309; AID594892; AID594893
Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)	Ki	0.0008	0.0000	0.0282	0.5900	AID1180669; AID1657084; AID302759; AID431190; AID444307; AID594894; AID754796; AID772350
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain B, Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)	Kd	0.0200	0.0200	0.0200	0.0200	AID977611
Chain C, Receptor activity-modifying protein 1	Homo sapiens (human)	Kd	0.0200	0.0200	0.0200	0.0200	AID977611
Chain A, Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)	Kd	0.0200	0.0200	0.0200	0.0200	AID977611
Chain D, Receptor activity-modifying protein 1	Homo sapiens (human)	Kd	0.0200	0.0200	0.0200	0.0200	AID977611
Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)	Kd	0.0028	0.0001	0.0019	0.0037	AID1180679; AID1180712
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
angiogenesis	Receptor activity-modifying protein 1	Homo sapiens (human)
calcium ion transport	Receptor activity-modifying protein 1	Homo sapiens (human)
intracellular protein transport	Receptor activity-modifying protein 1	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Receptor activity-modifying protein 1	Homo sapiens (human)
regulation of G protein-coupled receptor signaling pathway	Receptor activity-modifying protein 1	Homo sapiens (human)
protein transport	Receptor activity-modifying protein 1	Homo sapiens (human)
receptor internalization	Receptor activity-modifying protein 1	Homo sapiens (human)
positive regulation of protein glycosylation	Receptor activity-modifying protein 1	Homo sapiens (human)
protein localization to plasma membrane	Receptor activity-modifying protein 1	Homo sapiens (human)
amylin receptor signaling pathway	Receptor activity-modifying protein 1	Homo sapiens (human)
calcitonin gene-related peptide receptor signaling pathway	Receptor activity-modifying protein 1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Receptor activity-modifying protein 1	Homo sapiens (human)
cellular response to hormone stimulus	Receptor activity-modifying protein 1	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
angiogenesis	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
calcium ion transport	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
cell surface receptor signaling pathway	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
heart development	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
protein transport	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
receptor internalization	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
cellular response to sucrose stimulus	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
calcitonin gene-related peptide receptor signaling pathway	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
adrenomedullin receptor signaling pathway	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
vascular associated smooth muscle cell proliferation	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
calcitonin gene-related peptide receptor activity	Receptor activity-modifying protein 1	Homo sapiens (human)
protein binding	Receptor activity-modifying protein 1	Homo sapiens (human)
amylin receptor activity	Receptor activity-modifying protein 1	Homo sapiens (human)
calcitonin gene-related peptide binding	Receptor activity-modifying protein 1	Homo sapiens (human)
coreceptor activity	Receptor activity-modifying protein 1	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adrenomedullin receptor activity	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
calcitonin gene-related peptide receptor activity	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
G protein-coupled receptor activity	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
calcitonin receptor activity	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
protein binding	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
adrenomedullin binding	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Receptor activity-modifying protein 1	Homo sapiens (human)
plasma membrane	Receptor activity-modifying protein 1	Homo sapiens (human)
cell surface	Receptor activity-modifying protein 1	Homo sapiens (human)
receptor complex	Receptor activity-modifying protein 1	Homo sapiens (human)
CGRP receptor complex	Receptor activity-modifying protein 1	Homo sapiens (human)
cell surface	Receptor activity-modifying protein 1	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular region	Calcitonin gene-related peptide 1	Homo sapiens (human)
plasma membrane	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
cytoplasm	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
lysosome	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
endosome	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
endoplasmic reticulum	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
plasma membrane	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
adrenomedullin receptor complex	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
CGRP receptor complex	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
plasma membrane	Calcitonin gene-related peptide type 1 receptor	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (100)

Assay ID	Title	Year	Journal	Article
AID1180677	Antagonist activity against human CGRP receptor in presence of 50% human serum by cell based cAMP accumulation assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID431190	Displacement of [125I]human CGRP from human CLR expressed in HEK293 cells coexpressing human RAMP1	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
AID1068963	Clearance in iv dosed rat	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.
AID1180740	Antimigraine activity in migraine patient assessed as pain relief incidence at 280 mg after 2 hrs (Rvb = 33.4%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180735	Antimigraine activity in migraine patient assessed as pain relief incidence at 150 mg after 2 hrs (Rvb = 32.9%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1657086	Oral bioavailability in dog	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID302762	Ratio of IC50 for human CL receptor in E10 cells over IC50 human CL receptor in E10 cells in presence of 50% human serum	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180682	Inhibition of capsaicin-induced dermal vasodilation in rhesus monkey model by laser Doppler imaging method	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180675	Selectivity for human CGRP receptor over AM2 receptor (unknown origin)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1657089	Protein binding in human plasma assessed as unbound fraction	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID1180681	Binding affinity to human CGRP receptor using [3H]-labeled compound assessed as receptor binding half life	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180679	Reversible saturable binding affinity to human CGRP receptor using [3H]-labeled compound	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID444308	Antagonist activity at human CLR expressed in HEK293 cells coexpressing human RAMP1 assessed as inhibition of human CGRPalpha-induced cAMP production after 5 mins by scintillation proximity assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines.
AID1180737	Antimigraine activity in migraine patient assessed as pain freedom incidence at 140 mg after 2 hrs (Rvb = 10.2%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID302768	Clearance in dog at 1 mg/kg, po or 0.5 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID625501	Inhibition of human CGRP receptor expressed in huamn HEK293 cells coexpressing CLR/RAMP1 assessed as inhibition of CGRP-stimulated cAMP production after 1 hr	2011	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22	Identification of a novel RAMP-independent CGRP receptor antagonist.
AID1180738	Antimigraine activity in migraine patient assessed as pain freedom incidence at 280 mg after 2 hrs (Rvb = 10.2%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180687	Clearance in rat at 15 mg/kg, po or 2 mg/kg, iv	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180733	Antimigraine activity in migraine patient assessed as pain freedom incidence at 150 mg after 2 hrs (Rvb = 10.7%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1657094	Volume of distribution in human at 2.5 mg	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID772348	Fraction unbound in monkey plasma by equillibrium dialysis method	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.
AID1180707	Antimigraine activity in migraine patient assessed as induction pain relief at 150 mg after 2 hrs	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID594891	Oral bioavailability in rat at 10 mg/kg, po administered as a suspension in 1% aqueous methylcellulose	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
AID431192	Antagonist activity at human CLR expressed in HEK293 cells coexpressing human RAMP1 assessed as inhibition of human CGRPalpha-induced cAMP production after 30 mins by scintillation proximity assay in presence of 50% human serum	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
AID625500	Displacement of [125I]adrenomedullin form CGRP receptor in human SK-N-MC cell membrane by competitive binding assay	2011	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22	Identification of a novel RAMP-independent CGRP receptor antagonist.
AID665650	Selectivity ratio of Ki for rat CGRP receptor to Ki for human CGRP receptor	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.
AID594894	Displacement of [125I]-CGRP from human recombinant CGRP receptor	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
AID302765	Clearance in rat at 10 mg/kg, po or 1 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1657097	Cmax in human at 2.5 mg	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID1180689	Clearance in monkey at 5 mg/kg, po or 10 mg/kg, iv	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID431191	Antagonist activity at human CLR expressed in HEK293 cells coexpressing human RAMP1 assessed as inhibition of human CGRPalpha-induced cAMP production after 30 mins by scintillation proximity assay	2009	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 19, Issue:16	The identification of potent, orally bioavailable tricyclic CGRP receptor antagonists.
AID302770	Clearance in rhesus monkey at 0.5 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180704	Antimigraine activity in migraine patient assessed as induction pain relief at 300 mg after 2 hrs	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID302760	Antagonist activity at human CL receptor expressed in E10 cells assessed as CGRP-stimulated cAMP production	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180731	Antimigraine activity in migraine patient assessed as pain relief incidence at 300 mg after 2 hrs (Rvb = 27.7%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180683	Potency shift index, ratio of EC50 for inhibition of capsaicin-induced dermal vasodilation in rhesus monkey model to IC50 against human CGRP receptor in presence of 50% human serum by cell based cAMP accumulation assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID594899	Aqueous solubility of the compound at pH 7.4	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
AID302769	Inhibition of capsaicin-induced increase in dermal blood flow in iv dosed rhesus monkey	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180723	Antimigraine activity in migraine patient assessed as pain freedom incidence at 300 mg after 2 hrs (Rvb = 14.3%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180736	Antimigraine activity in migraine patient assessed as pain relief incidence at 300 mg after 2 hrs (Rvb = 32.9%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID594892	Antagonist activity at CGRP receptor assessed as inhibition of CGRP-stimulated cAMP production by cell based assay in presence of 50% human serum	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
AID772346	Ratio of AUC in rhesus monkey CSF to AUC in rhesus monkey plasma	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.
AID1180676	Antagonist activity against human CGRP receptor by cell based cAMP accumulation assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID772350	Displacement of [125I]-hCGRP from human CGRP receptor expressed in HEK293 cells	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.
AID1180674	Selectivity for human CGRP receptor over AM1 receptor (unknown origin)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180701	Terminal half life in iv dosed healthy human	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180700	Tmax in po dosed healthy human	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID665647	Ratio of Ki for rat CGRP receptor to Ki for rhesus monkey CGRP receptor	2012	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12	MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.
AID302759	Displacement of [125I]CGPR from human CL receptor expressed in HEK293 cells	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180705	Antimigraine activity in migraine patient assessed as induction pain relief at 600 mg after 2 hrs	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1657088	Oral bioavailability in human	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID302766	Half life in iv dosed rat at 10 mg/kg, po or 1 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180690	Half life in rat at 2 mg/kg, iv	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180725	Antimigraine activity in migraine patient assessed as pain relief incidence at 300 mg after 2 hrs (Rvb = 46.3%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180686	Oral bioavailability in monkey at 5 mg/kg	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID302763	Oral bioavailability in rat at 10 mg/kg	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180678	Unbound fraction in human plasma	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180734	Antimigraine activity in migraine patient assessed as pain freedom incidence at 300 mg after 2 hrs (Rvb = 10.7%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID302764	Oral bioavailability in dog at 1 mg/kg	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180727	Antimigraine activity in migraine patient assessed as pain freedom incidence at 150 mg after 2 hrs (Rvb = 9.6%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180739	Antimigraine activity in migraine patient assessed as pain relief incidence at 140 mg after 2 hrs (Rvb = 33.4%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180709	Toxicity in migraine patient assessed as incidence of drug-related adverse events at 300 mg	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180691	Half life in dog at 0.5 mg/kg, iv	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180692	Half life in monkey at 10 mg/kg, iv	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID625594	Inhibition of rat CGRP	2011	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22	Identification of a novel RAMP-independent CGRP receptor antagonist.
AID1180702	Oral bioavailability in healthy human at 150 to 200 mg	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1068964	Cmax in rat at 10 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.
AID1180718	Cmax in healthy human at 150 mg	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID302767	Tmax in po dosed rat at 10 mg/kg, po or 1 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID594893	Antagonist activity at CGRP receptor assessed as inhibition of CGRP-stimulated cAMP production by cell based assay	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
AID772349	Efflux ratio of human MDR1-mediated drug transport from basolateral to apical side over apical to basolateral side in pig LLC cells expressing human MDR1 at 5 uM	2013	ACS medicinal chemistry letters, Sep-12, Volume: 4, Issue:9	[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.
AID754796	Antagonist activity at human CGRP receptor	2013	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11	Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migr
AID302761	Antagonist activity at human CL receptor expressed in E10 cells assessed as CGRP-stimulated cAMP production in presence of 50% human serum	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180669	Binding affinity to human CGRP receptor	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180688	Clearance in dog at 1 mg/kg, po or 0.5 mg/kg, iv	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180712	Antagonist activity against CGRP receptor assessed as inhibition of CGRP-mediated vasorelaxation in human coronary arteries	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180680	Binding affinity to human CGRP receptor using [3H]-labeled compound assessed as off rate constant	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1657085	Oral bioavailability in rat	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID1180728	Antimigraine activity in migraine patient assessed as pain freedom incidence at 300 mg after 2 hrs (Rvb = 9.6%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID444309	Antagonist activity at human CLR expressed in HEK293 cells coexpressing human RAMP1 assessed as inhibition of human CGRPalpha-induced cAMP production after 5 mins in presence of 50% human serum by scintillation proximity assay	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines.
AID302771	Half life in rhesus monkey at 0.5 mg/kg, iv	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl
AID1180730	Antimigraine activity in migraine patient assessed as pain relief incidence at 150 mg after 2 hrs (Rvb = 27.7%)	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180703	Inhibition of capsaicin-induced dermal vasodilation in human by laser Doppler imaging method	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180684	Oral bioavailability in rat at 15 mg/kg	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID1180673	Binding affinity to rhesus monkey CGRP receptor	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID594895	Apparent permeability of compound	2011	Bioorganic & medicinal chemistry letters, May-01, Volume: 21, Issue:9	Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918.
AID1657084	Inhibition of human CLR/RAMP1	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID1657095	Clearance in human plasma at 2.5 mg	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID1068969	AUC in rat at 10 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.
AID1068962	Ratio of drug level in brain to plasma in rat administered as iv bolus measured after 0.25 to 1 hr post dosing	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.
AID1180685	Oral bioavailability in dog at 1 mg/kg	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
AID444307	Displacement of [125I]human CGRP from human CLR expressed in HEK 293 cells coexpressing human RAMP1 after 3 hrs by scintillation counting	2009	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 19, Issue:22	Optimization of azepanone calcitonin gene-related peptide (CGRP) receptor antagonists: development of novel spiropiperidines.
AID1068971	Oral bioavailability in rat at 10 mg/kg	2014	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 24, Issue:3	Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists.
AID1657096	Terminal half life in human at 2.5 mg	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2010	Structure (London, England : 1993), Sep-08, Volume: 18, Issue:9	Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	34 (35.42)	29.6817
2010's	57 (59.38)	24.3611
2020's	5 (5.21)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	19 (19.19%)	5.53%
Reviews	29 (29.29%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	51 (51.52%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
nickel Nickel: A trace element with the atomic symbol Ni, atomic number 28, and atomic weight 58.69. It is a cofactor of the enzyme UREASE.. nickel ion : A nickel atom having a net electric charge.. nickel atom : Chemical element (nickel group element atom) with atomic number 28.	2.1	1	0	metal allergen; nickel group element atom	epitope; micronutrient
urea pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.	2.1	1	0	isourea; monocarboxylic acid amide; one-carbon compound	Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	5.8	2	2	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	5.8	2	2	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	8.45	1	1	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
rizatriptan rizatriptan: structure given in first source; RN given refers to benzoate	6.9	4	1	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	11.18	3	1	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	2.05	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
tryptophan Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.	2.46	2	0	erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; tryptophan zwitterion; tryptophan	antidepressant; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; plant metabolite; Saccharomyces cerevisiae metabolite
caprolactam Caprolactam: Cyclic amide of caproic acid used in manufacture of synthetic fibers of the polyamide type. Can cause local irritation.. epsilon-caprolactam : A member of the class of caprolactams that is azepane substituted by an oxo group at position 2.	2.05	1	0	caprolactams	human blood serum metabolite
pyrroles 1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.	2.41	1	0	pyrrole; secondary amine
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	9.07	26	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
indazoles Indazoles: A group of heterocyclic aromatic organic compounds consisting of the fusion of BENZENE and PYRAZOLES.	3.15	1	0	indazole
substance p [no description available]	2.1	1	0	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	8.97	9	3	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
triazoles Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.	6.16	3	1	1,2,3-triazole
oxazolidin-2-one Oxazolidinones: Derivatives of oxazolidin-2-one. They represent an important class of synthetic antibiotic agents.. oxazolidin-2-one : An oxazolidinone that is 1,3-oxazolidine with an oxo substituent at position 2.. oxazolidinone : An oxazolidine containing one or more oxo groups.	8.35	8	3	carbamate ester; oxazolidinone	metabolite
eletriptan eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.	3.19	1	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
5-(1,1-dioxido-1,2-thiazinan-2-yl)-n-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide 5-(1,1-dioxido-1,2-thiazinan-2-yl)-N-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamide: structure in first source	2.06	1	0
capsaicin ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.	8.44	1	1	capsaicinoid	non-narcotic analgesic; TRPV1 agonist; voltage-gated sodium channel blocker
D-fructopyranose [no description available]	4.07	1	0	cyclic hemiketal; D-fructose; fructopyranose	sweetening agent
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	2.1	1	0	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	9.07	1	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
oxalates Oxalates: Derivatives of OXALIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that are derived from the ethanedioic acid structure.	3.16	1	0
mk 3207 [no description available]	4.28	5	0
piperidines Piperidines: A family of hexahydropyridines.	2.63	2	0
bms 694153 [no description available]	2.08	1	0
(5s,6s,9r)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta(b)pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo(4,5-b)pyridin-1-yl)piperidine-1-carboxylate [no description available]	3.19	1	0
mk-8825 [no description available]	2.07	1	0
atogepant atogepant : A secondary carboxamide resulting from the formal condensation of the carboxy group of (3'S)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic acid with the amino group of (3S,5S,6R)-3-amino-6-methyl-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-2-one. It is a selective oral, small-molecule antagonist of calcitonin gene-related peptide (CGRP) receptor that has been approved for the treatment of migraine.	3.82	2	0	azaspiro compound; organic heterotetracyclic compound; piperidones; secondary carboxamide; trifluorobenzene	calcitonin gene-related peptide receptor antagonist
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	2.1	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist

Condition	Indicated	Relationship Strength	Studies	Trials
Abdominal Migraine [description not available]	0	16.85	74	20
Migraine Disorders A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)	1	18.85	74	20
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	0	2.06	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	2.53	2	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Acute Liver Injury, Drug-Induced [description not available]	0	2.41	1	0
Adverse Drug Event [description not available]	0	2.41	1	0
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	2.41	1	0
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	2.41	1	0
Acute Disease Disease having a short and relatively severe course.	0	6.45	3	1
Contact Dermatitis [description not available]	0	2.1	1	0
Delayed Hypersensitivity [description not available]	0	2.1	1	0
Itching [description not available]	0	2.1	1	0
Hives [description not available]	0	2.1	1	0
Dermatitis, Contact A type of acute or chronic skin reaction in which sensitivity is manifested by reactivity to materials or substances coming in contact with the skin. It may involve allergic or non-allergic mechanisms.	0	2.1	1	0
Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.	0	2.1	1	0
Urticaria A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.	0	2.1	1	0
Premenstrual Tension A term used to describe the psychological aspects of PREMENSTRUAL SYNDROME, such as the indescribable tension, depression, hostility, and increased seizure activity in women with seizure disorder.	0	4.43	1	1
Premenstrual Syndrome A combination of distressing physical, psychologic, or behavioral changes that occur during the luteal phase of the menstrual cycle. Symptoms of PMS are diverse (such as pain, water-retention, anxiety, cravings, and depression) and they diminish markedly 2 or 3 days after the initiation of menses.	0	4.43	1	1
Neurogenic Inflammation Inflammation caused by an injurious stimulus of peripheral neurons and resulting in release of neuropeptides which affect vascular permeability and help initiate proinflammatory and immune reactions at the site of injury.	0	3.88	1	0
Light Sensitivity [description not available]	0	4.76	2	1
Auditory Hyperesthesia [description not available]	0	4.35	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	0	4.35	1	1
Acute Onset Aura Migraine [description not available]	0	2.05	1	0
Apoplexy [description not available]	0	2.05	1	0
Cardiovascular Stroke [description not available]	0	2.05	1	0
Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).	0	2.05	1	0
Migraine with Aura A subtype of migraine disorder, characterized by recurrent attacks of reversible neurological symptoms (aura) that precede or accompany the headache. Aura may include a combination of sensory disturbances, such as blurred VISION; HALLUCINATIONS; VERTIGO; NUMBNESS; and difficulty in concentrating and speaking. Aura is usually followed by features of the COMMON MIGRAINE, such as PHOTOPHOBIA; PHONOPHOBIA; and NAUSEA. (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)	0	2.05	1	0
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	0	2.05	1	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	3.44	1	1
Ache [description not available]	0	5.62	3	2
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	5.62	3	2
Bilateral Headache [description not available]	0	2.98	1	0
Headache The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.	0	2.98	1	0
Brain Vascular Disorders [description not available]	0	2.06	1	0
Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others.	0	2.06	1	0
Heart Disease, Ischemic [description not available]	0	3.45	1	1
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	0	3.45	1	1
Arteriosclerosis, Coronary [description not available]	0	4.37	1	1
Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.	0	9.37	1	1
Angina Pectoris, Stable [description not available]	0	4.37	1	1
Angina, Stable Persistent and reproducible chest discomfort usually precipitated by a physical exertion that dissipates upon cessation of such an activity. The symptoms are manifestations of MYOCARDIAL ISCHEMIA.	0	4.37	1	1
Chronic Illness [description not available]	0	2.99	1	0
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	0	2.99	1	0

telcagepant

Description

Cross-References

Synonyms (45)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (64)

Molecular Functions (26)

Ceullar Components (27)

Bioassays (100)

Research

Studies (96)

Study Types

telcagepant

Description

Cross-References

Synonyms (45)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (64)

Molecular Functions (26)

Ceullar Components (27)

Bioassays (100)

Research

Studies (96)

Study Types

Related Drugs (31)

Related Conditions (45)